Theodore S. Hong

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Figures 1-8 from Distinct Malignant Cell States and Myeloid Glutamate Signaling Associated with Aggressive Pancreatic Neuroendocrine Tumors

  2026-06-19

• Data from Distinct Malignant Cell States and Myeloid Glutamate Signaling Associated with Aggressive Pancreatic Neuroendocrine Tumors

  2026-06-19

• Supplementary Tables 1 from Distinct Malignant Cell States and Myeloid Glutamate Signaling Associated with Aggressive Pancreatic Neuroendocrine Tumors

  2026-06-19

• NRG-GI007: Phase I study of OBP-301, an oncolytic virus, and definitive chemoradiation in locally advanced esophageal cancer

  International Journal of Radiation Oncology*Biology*Physics · 2026-06-01

• Neoadjuvant Stereotactic Body Radiotherapy plus Immune Therapy Favorably Remodels the Hepatocellular Carcinoma Tumor Microenvironment

  Clinical Cancer Research · 2026-04-15

• Transitioning from neoadjuvant chemoradiation to perioperative chemotherapy for esophageal adenocarcinoma: Impact on margins and pathologic outcomes

  JTCVS Open · 2026-04-01

• Reply to: Yttrium-90 Radioembolization Provides Durable Local Control and Definitive Radiation Therapy

  Journal of Clinical Oncology · 2026-03-30

• Distinct Malignant Cell States and Myeloid Glutamate Signaling Associated with Aggressive Pancreatic Neuroendocrine Tumors

  Clinical Cancer Research · 2026-03-18

• Patient‐reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma

  Cancer · 2026-03-11

• Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters

  Journal of Clinical Oncology · 2026-03-05

• Tolerability and outcomes after neoadjuvant and definitive radiation of elderly patients with localized pancreatic cancer.

  Journal of Clinical Oncology · 2026-01-10

• NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-North America).

  Journal of Clinical Oncology · 2026-01-10

• Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo (FFX/bev) in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)— NRG-GI004/SWOG-S1610.

  Journal of Clinical Oncology · 2026-01-10 · 7 citations

• Alliance A022104/NRG-GI010, a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer (LARC): The Janus Rectal Cancer trial.

  Journal of Clinical Oncology · 2026-01-10

• Supplementary Figure S6 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer

  2025-11-25

• Supplementary Table S2 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer

  2025-11-25

• Supplementary Table S6 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer

  2025-11-25

• Supplementary Figure S3 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer

  2025-11-25

• Supplementary Figure S4 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer

  2025-11-25

• Supplementary Table S4 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer

  2025-11-25